Related Experiment Video

Updated: Feb 20, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

40.1K

The association of β-arrestin2 polymorphisms with response to antidepressant treatment in depressed patients

Anne-Cécile Petit1, Khalil El Asmar2, Denis J David3

  • 1CESP/UMR-S1178, Equipe "Dépression et Antidépresseurs", Univ Paris-Sud, Faculté de Médecine, INSERM, Le Kremlin Bicêtre, France; Service de Psychiatrie, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.

Progress in Neuro-Psychopharmacology & Biological Psychiatry
|October 17, 2017
PubMed

Insights

Genetic variations in the beta-arrestin 2 (ARRB2) gene are linked to antidepressant (AD) treatment response. Specific ARRB2 single nucleotide polymorphisms (SNPs) like rs4522461 and rs4790694 were associated with lower treatment efficacy in major depressive disorder patients.

Area of Science:

  • Pharmacogenetics
  • Neuroscience
  • Genetics

Background:

  • Personalized medicine for depression requires understanding genetic factors influencing antidepressant (AD) response.
  • Beta-arrestin 2 (ARRB2) is a key protein in neurotransmitter receptor signaling pathways relevant to AD action.

Purpose of the Study:

  • To investigate the association between five ARRB2 single nucleotide polymorphisms (SNPs) and treatment response to antidepressants.
  • To explore the role of ARRB2 genetic variations in the pharmacogenetics of major depressive disorder.

Main Methods:

  • Genotyping of five ARRB2 SNPs (rs1045280, rs2036657, rs4790694, rs3786047, rs452246) in 569 patients with major depressive episodes.
  • Assessed treatment response over 6 months using the Hamilton Depression Rating Scale (HDRS).
  • Statistical analysis including multivariate analysis to determine SNP-response associations.

Main Results:

  • Patients with GG/GT genotypes for rs4522461 showed significantly lower AD response (HDRS 10.9 vs 8.0, p=0.03).
  • Patients with AA/AC genotypes for rs4790694 also exhibited reduced AD response (HDRS 12.2 vs 9.6, p=0.02).
  • These findings highlight specific ARRB2 SNPs impacting treatment outcomes.

Conclusions:

  • Beta-arrestin 2 (ARRB2) genetic polymorphisms are associated with variable responses to antidepressant treatment.
  • These ARRB2 SNPs may serve as potential biomarkers for predicting AD efficacy in depression.
  • Further research into ARRB2's role can advance personalized depression treatment strategies.
Keywords:
ARRB2AntidepressantBeta-arrestinMajor depressive disorderPharmacogenetics

More Related Videos

Developing a Rat Model for Bipolar Disorder04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.5K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

658

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
25
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
991
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
20
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.7K
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
132.4K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.0K